2022年9月30日

公司正在开发第一个处方可穿戴治疗慢性眩晕。最近，Otolith实验室赚了2000万美元。该公司已完成由晨兴投资(Morningside Ventures)领投的2000万美元a轮融资。基于商人Mark Cuban和领先的耳鼻喉科医生先前的投资，所得收益将用于支持该公司正在进行的临床项目，预计美国食品和药物管理局(FDA)将批准，并首次商业推出使用其非侵入性前庭系统掩体(nVSM)技术治疗慢性眩晕的处方可穿戴设备。Otolith Labs首席执行官兼创始人Sam Owen表示:“由Morningside投资专家团队牵头的A轮融资的结束，以及我们现有投资者的持续支持，突显了首个可穿戴解决方案的增长势头，该解决方案对数百万美国人产生了不利影响。”“在我们的试点研究中，反应者报告说他们的眩晕症状立即得到缓解。这些研究的数据支持我们计划发布nVSM技术，作为一种有效且耐受性良好的慢性眩晕疗法。我们创立这家公司是为了改善人们的生活，在晨兴的支持下，我们正在朝着实现这一愿景的方向前进。”Otolith实验室的nVSM技术旨在为慢性眩晕提供即时症状缓解。nVSM通过校准振动对前庭系统进行局部机械刺激。 The company received FDA Breakthrough Device Designation last year for the prescription treatment of chronic vertigo. This designation, which can accelerate the development, assessment, and review of medical devices for pre-market approval, is only granted for devices that address an unmet need and show the potential to provide more effective treatment of life-threatening diseases or irreversibly debilitating conditions. Otolith Labs will soon be enrolling participants for its pivotal study to further evaluate the effectiveness of nVSM as a treatment of chronic vertigo. “Otolith Labs’ mission is to make daily living easier for the millions of Americans suffering from the symptoms of chronic vertigo and other vestibulogenic conditions. Chronic vertigo is a condition that prevents people from performing activities of daily living and has significant quality of life and economic impact,” said Anthony Aiudi at Morningside Ventures. “The team at Otolith Labs has developed a technology that could change how chronic vertigo is treated today. Otolith Labs is leading the charge in developing a noninvasive and non-pharmacological therapy for those who have chronic vertigo and we look forward to being a part of this journey.” In Otolith’s pilot studies, which enrolled approximately 100 subjects, nVSM showed an immediate and robust therapeutic benefit over placebo, with those in the active group more than three times as likely to report improved symptoms than those in the placebo group (p > 0.05). Otolith is working closely with the leaders of the otolaryngology and medical community to ensure the rapid development and future adoption of this therapy to improve patients’ lives. “As someone who sees chronic vertigo patients on a regular basis, I know how frustratingly few and effective treatment options are available today. I have been following Otolith Labs for 5 years and I am very encouraged by their development progress of their treatment for this debilitating condition,” said Dr. Michael Hoffer, professor of Otolaryngology and Neurological Surgery at the University of Miami’s Miller School of Medicine. Otolith Labs is developing prescription medical devices for the treatment of vestibular disorders. Its flagship product, a patented noninvasive Vestibular System Masking (nVSM) technology, is intended to be the first prescription wearable device for the treatment of chronic vertigo, a symptom that affects more than 4 million Americans. The device uses precisely tuned vibrations to interact with the acceleration sensors in the inner ear, mitigating the symptoms of vertigo. Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai, and London, the firm invests globally. Trending